JP2012515720A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012515720A5 JP2012515720A5 JP2011546429A JP2011546429A JP2012515720A5 JP 2012515720 A5 JP2012515720 A5 JP 2012515720A5 JP 2011546429 A JP2011546429 A JP 2011546429A JP 2011546429 A JP2011546429 A JP 2011546429A JP 2012515720 A5 JP2012515720 A5 JP 2012515720A5
- Authority
- JP
- Japan
- Prior art keywords
- sorbate
- benzoate
- acid
- benzoic acid
- aminobenzoate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14593109P | 2009-01-20 | 2009-01-20 | |
| US61/145,931 | 2009-01-20 | ||
| PCT/US2010/021420 WO2010085452A1 (en) | 2009-01-20 | 2010-01-19 | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012515720A JP2012515720A (ja) | 2012-07-12 |
| JP2012515720A5 true JP2012515720A5 (enExample) | 2013-02-28 |
| JP5675650B2 JP5675650B2 (ja) | 2015-02-25 |
Family
ID=42354348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011546429A Expired - Fee Related JP5675650B2 (ja) | 2009-01-20 | 2010-01-19 | 向精神薬の働きを向上させるソルビン酸、安息香酸及びその誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US9649304B2 (enExample) |
| EP (3) | EP3006024B1 (enExample) |
| JP (1) | JP5675650B2 (enExample) |
| CN (1) | CN102292094B (enExample) |
| AU (1) | AU2010206886B2 (enExample) |
| BR (1) | BRPI1007173A2 (enExample) |
| CA (2) | CA3037010A1 (enExample) |
| DK (2) | DK2389187T3 (enExample) |
| ES (2) | ES2731228T3 (enExample) |
| HR (2) | HRP20170089T1 (enExample) |
| MX (3) | MX353752B (enExample) |
| WO (1) | WO2010085452A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2731228T3 (es) | 2009-01-20 | 2019-11-14 | Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct | Acido benzoico o sales del mismo para mejorar la actividad de un producto farmacéutico |
| WO2011017319A1 (en) * | 2009-08-03 | 2011-02-10 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods of treating disorders associated with protein polymerization |
| US8809617B2 (en) | 2009-11-05 | 2014-08-19 | The University of Pittsburgh—Of the Commonwealth System of Higher Education | Automated high-content live animal drug screening using C. elegans |
| US9072772B2 (en) | 2009-11-05 | 2015-07-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating disorders associated with protein aggregation |
| JP5751109B2 (ja) * | 2011-09-20 | 2015-07-22 | ニプロ株式会社 | 生体試料中の馬尿酸およびメチル馬尿酸のそれぞれの濃度を測定する方法 |
| HK1214505A1 (zh) * | 2012-08-06 | 2016-07-29 | S1制药有限公司 | 治療方案 |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
| WO2014168727A1 (en) * | 2013-03-15 | 2014-10-16 | Shire Llc | Fixed dose combination treatment for schizophrenia |
| WO2015147742A1 (en) * | 2014-03-24 | 2015-10-01 | Kaohsiung Chang Gung Memorial Hospital | Use of benzoic acid salt in the manufactue of a composition for preventing or treating dementia or mild cognitive impairment |
| CN108351862B (zh) | 2015-08-11 | 2023-08-22 | 科格诺亚公司 | 利用人工智能和用户输入来确定发育进展的方法和装置 |
| US11972336B2 (en) | 2015-12-18 | 2024-04-30 | Cognoa, Inc. | Machine learning platform and system for data analysis |
| US10653639B2 (en) | 2016-05-16 | 2020-05-19 | Cv Sciences, Inc. | Pharmaceutical formulations containing cannabidiol and nicotine for treating smokeless tobacco addiction |
| EP3468550A4 (en) * | 2016-06-13 | 2020-02-12 | Syneurx International (Taiwan) Corp. | USE OF LITHIUM BENZOATE FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM |
| TWI736635B (zh) | 2016-06-13 | 2021-08-21 | 心悅生醫股份有限公司 | 苯甲酸鋰之共晶及其用途 |
| KR102403048B1 (ko) | 2016-06-13 | 2022-05-26 | 신유알엑스 인터내셔널 (타이완) 코포레이션 | 벤조산나트륨의 공-결정 및 그의 용도 |
| KR20190066608A (ko) * | 2016-09-23 | 2019-06-13 | 델포어, 인코포레이티드 | 소분자 치료제 화합물 조성물 |
| US11369579B2 (en) | 2016-10-24 | 2022-06-28 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| US10336679B2 (en) * | 2016-10-24 | 2019-07-02 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| WO2018090009A1 (en) | 2016-11-14 | 2018-05-17 | Cognoa, Inc. | Methods and apparatus for evaluating developmental conditions and providing control over coverage and reliability |
| TW202345829A (zh) * | 2016-12-02 | 2023-12-01 | 美商紐羅克里生物科學有限公司 | 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途 |
| PL3338768T3 (pl) | 2016-12-20 | 2020-05-18 | Lts Lohmann Therapie-Systeme Ag | Transdermalny system terapeutyczny zawierający asenapinę |
| ES3001152T3 (es) | 2016-12-20 | 2025-03-04 | Lts Lohmann Therapie Systeme Ag | Sistema terapéutico transdérmico que contiene asenapina y polisiloxano o poliisobutileno |
| WO2018148365A1 (en) | 2017-02-09 | 2018-08-16 | Cognoa, Inc. | Platform and system for digital personalized medicine |
| TWI626043B (zh) * | 2017-06-13 | 2018-06-11 | 心悅生醫股份有限公司 | 苯甲酸鋰用於治療中樞神經系統疾病的用途 |
| WO2019002204A1 (en) | 2017-06-26 | 2019-01-03 | Lts Lohmann Therapie-Systeme Ag | TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER |
| JP6550426B2 (ja) * | 2017-07-26 | 2019-07-24 | カオシュン・チャン・グン・メモリアル・ホスピタル | 認知症または軽度認知障害を予防または治療する組成物を製造するための安息香酸塩の使用 |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| MX2020003421A (es) | 2017-10-10 | 2020-07-20 | Neurocrine Biosciences Inc | Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2). |
| US10098861B1 (en) | 2017-10-24 | 2018-10-16 | Syneurx International (Taiwan) Corp. | Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof |
| EP3713556A4 (en) * | 2017-11-22 | 2021-10-20 | Chieh-Hsin Lin | BENZOIC ACID OR A SALT AND DERIVATIVE THEREOF FOR USE IN THE PREVENTION OR TREATMENT OF DEPRESSION |
| WO2019113084A1 (en) | 2017-12-05 | 2019-06-13 | Sunovion Pharmaceuticals Inc. | Crystal forms and production methods thereof |
| CN118593482A (zh) | 2017-12-05 | 2024-09-06 | 赛诺维信制药公司 | 非外消旋混合物及其用途 |
| EP3810099A1 (en) | 2018-06-20 | 2021-04-28 | LTS Lohmann Therapie-Systeme AG | Transdermal therapeutic system containing asenapine |
| AU2019291060B2 (en) | 2018-06-20 | 2024-09-05 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| KR102051624B1 (ko) * | 2018-11-30 | 2019-12-02 | 아밀로이드솔루션 주식회사 | 트리플루프로마진 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 퇴행성 뇌질환 치료용 약학 조성물 |
| AU2020248351B2 (en) | 2019-03-22 | 2025-09-25 | Cognoa, Inc. | Personalized digital therapy methods and devices |
| JP2022529781A (ja) | 2019-04-17 | 2022-06-24 | コンパス パスファインダー リミテッド | サイロシビンによるうつ病及び他の様々な障害の治療 |
| MX2021014774A (es) | 2019-06-04 | 2022-02-03 | Sunovion Pharmaceuticals Inc | Formulaciones de liberacion modificada y usos de las mismas. |
| CA3153086A1 (en) | 2019-09-06 | 2021-03-11 | Cognoa, Inc. | Methods, systems, and devices for the diagnosis of behavioral disorders, developmental delays, and neurologic impairments |
| CN119949562A (zh) * | 2020-03-27 | 2025-05-09 | 深圳市合瑞生物科技有限公司 | 组合物及其制品 |
| WO2021245697A1 (en) | 2020-06-01 | 2021-12-09 | Celagenex Research (India) Pvt. Ltd. | Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling |
| JP2024532418A (ja) * | 2021-08-30 | 2024-09-05 | エルテーエス ローマン テラピー－ジステーメ アーゲー | グアンファシン及びモノカルボン酸を含むグアンファシンの経皮投与のための経皮治療システム |
| EP4447952A4 (en) * | 2021-12-16 | 2025-11-19 | Us Gov Veterans Affairs | Benzoic acid salts for the treatment of injuries and disorders of the nervous system |
| US20240120050A1 (en) * | 2022-10-07 | 2024-04-11 | Insight Direct Usa, Inc. | Machine learning method for predicting a health outcome of a patient using video and audio analytics |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3498989A (en) * | 1969-04-16 | 1970-03-03 | American Home Prod | Certain 8-substituted-2-alkyl-3-benzoyl esters of ecgonine and derivatives thereof |
| US3870715A (en) | 1972-03-09 | 1975-03-11 | Nikolaus R Hansl | Substituted amino ethyl meta benzoic acid esters |
| US4041174A (en) * | 1974-08-16 | 1977-08-09 | Rom-Amer Pharmaceuticals, Ltd. | Method of treating depression |
| US5204356A (en) | 1985-07-24 | 1993-04-20 | Glaxo Group Limited | Treatment of anxiety |
| US6150354A (en) * | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
| GB8819494D0 (en) | 1988-08-16 | 1988-09-21 | Ucb Sa | Use of 2-amino-4-morpholino-6-propyl-1 3 5-triazines for preparation of psychotropic medicaments |
| US6746678B1 (en) * | 1991-02-22 | 2004-06-08 | Howard K. Shapiro | Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments |
| FR2700117B1 (fr) | 1993-01-07 | 1995-02-03 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens. |
| DE4340273A1 (de) | 1993-11-26 | 1995-06-01 | Karla Dr Lehmann | Arzneimittel zur Prophylaxe des Morbus Alzheimer und zur Verhütung des Fortschreitens dieser Erkrankung |
| US5453425A (en) | 1994-07-11 | 1995-09-26 | Janssen Pharmaceutica N.V. | Risperidone oral formulation |
| WO2001041707A2 (en) * | 1999-12-08 | 2001-06-14 | Vanderbilt University | Modulation of in vivo glutamine and glycine levels in the treatment of autism |
| US20040156872A1 (en) * | 2000-05-18 | 2004-08-12 | Elan Pharma International Ltd. | Novel nimesulide compositions |
| CZ2003396A3 (cs) | 2000-07-21 | 2003-05-14 | H. Lundbeck A/S | Inhibitory transportu glycinu |
| MXPA03001337A (es) | 2000-08-14 | 2005-06-30 | Teva Pharma | Preparacion de risperidona. |
| US20030185754A1 (en) * | 2001-01-16 | 2003-10-02 | Genset, S.A. | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
| JP2004537275A (ja) * | 2001-01-16 | 2004-12-16 | ジェンセット | Ｄ−アミノ酸オキシダーゼおよびｄ−アスパラギン酸オキシダーゼのアンタゴニストを使用するｃｎｓ障害の処置 |
| WO2003039540A2 (en) * | 2001-11-09 | 2003-05-15 | Sepracor Inc. | D-amino acid oxidase inhibitors for learning and memory |
| AU2002339696A1 (en) | 2001-12-03 | 2003-06-17 | Genset S.A. | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors |
| US20070053976A1 (en) * | 2002-05-17 | 2007-03-08 | Eisai R & D Management Co., Ltd. | Novel combination of drugs as antidepressant |
| US7053122B2 (en) | 2002-08-09 | 2006-05-30 | Pfizer Inc | Therapeutic use of aryl amino acid derivatives |
| US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| AU2003274353B2 (en) * | 2002-10-24 | 2007-04-05 | Merz Pharma Gmbh & Co. Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| WO2004065348A1 (en) * | 2003-01-23 | 2004-08-05 | Pfizer Products Inc. | Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof |
| CA2527114A1 (en) * | 2003-05-30 | 2004-12-16 | Microbia, Inc. | Methods for the protection of memory and cognition |
| WO2005000205A2 (en) | 2003-06-02 | 2005-01-06 | Samaritan Pharmaceuticals, Inc. | Methods and compositions for modulating serum cortisol levels |
| ZA200605384B (en) | 2003-12-29 | 2007-10-31 | Sepracor Inc | Benzo[D]isoxazol-3-OL DAAO inhibitors |
| ATE504588T1 (de) | 2004-01-27 | 2011-04-15 | Synthon Bv | Stabile salze von olanzapin |
| CA2556870C (en) * | 2004-02-18 | 2014-01-28 | Timothy J. Barberich | Dopamine-agonist combination therapy for improving sleep quality |
| US7825135B2 (en) | 2004-03-24 | 2010-11-02 | Merck Sharp & Dohme Limited | Heteroaryl piperidine glycine transporter inhibitors |
| US20050250738A1 (en) * | 2004-05-06 | 2005-11-10 | Mosher Gerold L | Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin |
| WO2006096439A2 (en) | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
| WO2006129160A2 (en) * | 2005-06-01 | 2006-12-07 | Aurobindo Pharma Limited | Stable aqueous oral solution of risperidone |
| US20110045065A1 (en) | 2005-07-11 | 2011-02-24 | Ashok Vasantray Vyas | Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof |
| US7811604B1 (en) | 2005-11-14 | 2010-10-12 | Barr Laboratories, Inc. | Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same |
| EP1976495A2 (en) * | 2006-01-06 | 2008-10-08 | Aarhus Universitet | Compounds acting on the serotonin transporter |
| GB0603181D0 (en) * | 2006-02-17 | 2006-03-29 | Merck Sharp & Dohme | Treatment of neurodegenerative and psychiatric diseases |
| US20080045512A1 (en) | 2006-08-09 | 2008-02-21 | Pfizer Inc. | Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane |
| US20080070984A1 (en) | 2006-09-15 | 2008-03-20 | Tran Pierre V | Compositions and Methods of Treating Schizophrenia |
| ES2731228T3 (es) | 2009-01-20 | 2019-11-14 | Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct | Acido benzoico o sales del mismo para mejorar la actividad de un producto farmacéutico |
-
2010
- 2010-01-19 ES ES15192644T patent/ES2731228T3/es active Active
- 2010-01-19 CN CN2010800050053A patent/CN102292094B/zh not_active Expired - Fee Related
- 2010-01-19 CA CA3037010A patent/CA3037010A1/en active Pending
- 2010-01-19 BR BRPI1007173A patent/BRPI1007173A2/pt not_active IP Right Cessation
- 2010-01-19 DK DK10733788.3T patent/DK2389187T3/en active
- 2010-01-19 EP EP15192644.1A patent/EP3006024B1/en active Active
- 2010-01-19 MX MX2011007712A patent/MX353752B/es active IP Right Grant
- 2010-01-19 EP EP15192647.4A patent/EP3006023B1/en active Active
- 2010-01-19 MX MX2017002151A patent/MX374638B/es unknown
- 2010-01-19 ES ES10733788.3T patent/ES2615884T3/es active Active
- 2010-01-19 EP EP10733788.3A patent/EP2389187B1/en active Active
- 2010-01-19 AU AU2010206886A patent/AU2010206886B2/en not_active Ceased
- 2010-01-19 DK DK15192644.1T patent/DK3006024T3/da active
- 2010-01-19 JP JP2011546429A patent/JP5675650B2/ja not_active Expired - Fee Related
- 2010-01-19 MX MX2017002152A patent/MX380715B/es unknown
- 2010-01-19 US US12/689,957 patent/US9649304B2/en not_active Expired - Fee Related
- 2010-01-19 HR HRP20170089TT patent/HRP20170089T1/hr unknown
- 2010-01-19 CA CA2750028A patent/CA2750028C/en active Active
- 2010-01-19 WO PCT/US2010/021420 patent/WO2010085452A1/en not_active Ceased
-
2014
- 2014-11-24 US US14/552,298 patent/US9675604B2/en active Active
-
2017
- 2017-01-19 US US15/409,655 patent/US10039730B2/en active Active
- 2017-01-19 US US15/409,775 patent/US10149845B2/en active Active
-
2018
- 2018-11-21 US US16/197,674 patent/US11529342B2/en active Active
-
2019
- 2019-05-21 HR HRP20190933TT patent/HRP20190933T1/hr unknown